Subsidised access to TNFα inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible?

• Australian Pharmaceutical Benefits Advisory Committee, School of Pharmacy, University of South Australia, Adelaide, SA 5000.

---

• 1. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumour necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-259.
• 2. Moreland, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med 1999; 130: 478-486.